Pharmaceutical

KeyBioscience and Eli Lilly extend partnership for obesity treatments

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated disorders.

Oct 12, 2024 - 04:00
KeyBioscience and Eli Lilly extend partnership for obesity treatments
KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated disorders.
Read the original article

Tags:

Previous Article

Booster Therapeutics to develop proteasome activator medicines

Next Article

CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs

STAT+: FDA cites cancer links in seeking to withdraw ap...

Nov 7, 2023

UK launches national full-body scan platform to accelerate drug discovery

UK launches national full-body scan platform to acceler...

Oct 5, 2023

Abeona’s cell therapy secures priority approval date for rare skin disorder

Abeona’s cell therapy secures priority approval date fo...

Nov 28, 2023